Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Tirzepatide vs Dulaglutide

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

This combination is flagged

GLP-1 agonist + insulin or sulfonylureas: High risk per peptide research literature. Hypoglycemia risk: GLP-1 enhances glucose-dependent insulin secretion; stacking with exogenous insulin or secretagogues can drive severe lows.

Data-derived verdict

Tirzepatide and Dulaglutide share the glp-1 class and carry roughly equivalent evidence (FDA-Approved / FDA-Approved). On the catalogued data layer Tirzepatide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Tirzepatide's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Tirzepatide

FDA-Approved

Dulaglutide

FDA-Approved

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: nausea; diarrhea; pancreatitis risk. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

Tirzepatide Dulaglutide
Class GIP/GLP-1 dual incretin agonist GLP-1 receptor agonist
Drug class Metabolic & Weight Metabolic & Weight
Mechanism Dual agonism at GIP and GLP-1 receptors; delays gastric emptying; enhances satiety; improves insulin sensitivity [1][2] GLP-1 receptor agonist fused to human IgG4 Fc
Route SC injection SC injection
Half-life ~5 days ~5 days
Dosage (research) 2.5 mg SC weekly (Mounjaro/Zepbound label starting dose, escalate by 2.5 mg monthly to label max 15 mg weekly per SURMOUNT escalation schedule) [1][2][3] 0.75 mg SC weekly (Trulicity label starting dose, escalate stepwise to 1.5, 3.0, then label max 4.5 mg weekly for additional glycemic control per AWARD trials)
Evidence tier FDA-Approved FDA-Approved
Research depth 451 indexed (PubMed 225 · CT 169 · EPMC 57) 311 indexed (PubMed 190 · CT 64 · EPMC 57)
Availability Prescription Prescription
Reported risks Nausea; vomiting; diarrhea; pancreatitis risk; gallbladder disease; thyroid C-cell tumor black-box warning [1][2] Nausea; diarrhea; pancreatitis risk; thyroid C-cell tumor warning

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Tirzepatide or Dulaglutide?

Tirzepatide and Dulaglutide share the glp-1 class and carry roughly equivalent evidence (FDA-Approved / FDA-Approved). On the catalogued data layer Tirzepatide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Tirzepatide's evidence base is currently denser.

What is the difference between Tirzepatide and Dulaglutide?

Tirzepatide is classed as GIP/GLP-1 dual incretin agonist; Dulaglutide is classed as GLP-1 receptor agonist. Reported mechanism: Tirzepatide, Dual agonism at GIP and GLP-1 receptors; delays gastric emptying; enhances satiety; improves insulin sensitivity; Dulaglutide, GLP-1 receptor agonist fused to human IgG4 Fc. Reported half-life: Tirzepatide, ~5 days; Dulaglutide, ~5 days. Routes in published studies: Tirzepatide, SC injection; Dulaglutide, SC injection.

Which has stronger evidence, Tirzepatide or Dulaglutide?

Tirzepatide and Dulaglutide sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Tirzepatide is graded FDA-Approved, with 90 cited sources on its reference page and 451 indexed studies. Dulaglutide is graded FDA-Approved, with 41 cited sources on its reference page and 311 indexed studies.

Which is more accessible, Tirzepatide or Dulaglutide?

Both Tirzepatide and Dulaglutide are FDA-approved drugs. Catalog status: Tirzepatide, Prescription; Dulaglutide, Prescription.

Are Tirzepatide and Dulaglutide ever combined?

Tirzepatide and Dulaglutide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…